Efficacy and safety of budesonide for eosinophilic esophagitis: an updated systematic review and meta-analysis
Budesonide effectively induces histologic and clinical remission in EoE but does not reverse fibrosis. While generally safe, long-term adrenal monitoring is warranted due to cortisol suppression. GRADE evaluation suggested moderate-to-high certainty for efficacy outcomes and moderate certainty for safety outcomes. Persistent symptoms in fibrostenotic disease highlight the need for adjunct therapies. Future research should optimize dosing regimens and evaluate combination strategies.
Authors
- Muhammad Usama Shahid (ORCID: https://orcid.org/0000-0003-3069-5467)
- Muhammad Sarwat Mirza
- Kanza Farhan (ORCID: https://orcid.org/0009-0002-6211-7522)
- Barka Sajid (ORCID: https://orcid.org/0009-0001-2304-2196)
- Izere Salomon (ORCID: https://orcid.org/0000-0003-3067-560X)
- Muhammad Burhan Tariq
- Rabeya Farid
- MS Tanveer
Institutions
- Jinnah Sindh Medical University (PK)
- University of Kigali (RW)
- Dow University of Health Sciences (PK)
- University of Rwanda (RW)
- Rwanda Biomedical Center (RW)
Publication Details
- Journal
- Annals of Medicine and Surgery
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1097/ms9.0000000000004577
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 0.00